/

XBIO

Xenetic Biosciences, Inc.Closed

2.10−0.04 −1.87%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

2.14

Prev close

2.14

Day range

2.042.18

52-week range

1.875.28

Volume

27.19K0.31×

Mkt cap

4.92M

P/E ttm

—

Fwd P/E

-3.18

EPS ttm

-1.15

Div yield

0.00%

Earnings

—

From 52w high

−60.23%

Price Chart

Yahoo Finance · delayed

XBIOOct 13, 2026O 2.14H 2.17L 2.04C 2.10−0.02 (−0.94%)Vol 33.90K

SMA 503.16
SMA 2002.86

1Y change −60.89% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

XBIO Xenetic Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −0.94%
1 month: −46.15%
3 months: −30.00%
6 months: −35.58%
Year to date: −3.23%
1 year: −60.89%

Valuation & ownership

Market cap: 4.92M
Enterprise value: −1.55M
P/E (ttm): —
Forward P/E: -3.18
PEG ratio: —
Price / book: 0.81
Price / sales (ttm): 1.51
EV / EBITDA: —
EPS (ttm): -1.15
EPS (forward): -0.6600
Beta (5y monthly): 2.20
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 2.34M
Float: 1.89M
Short % of float: 0.57%
Short ratio (days): 0.08
Held by insiders: 11.43%
Held by institutions: 6.49%
Avg volume (3m): 88.38K
50-day average: 3.17
200-day average: 2.86
52-week change: −60.89%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 34.0
vs 50-day SMA: −33.56%
vs 200-day SMA: −26.45%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 11.95%
Realised vol (20d, ann.): 254.3%
From 52-week high: −64.41%
From 52-week low: +12.30%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 3.26M
Revenue growth (yoy): +12.00%
Earnings growth (yoy): —
Gross margin: 100.00%
Operating margin: -147.09%
Profit margin: -75.91%

DES

About Xenetic Biosciences, Inc.

Yahoo Finance profile

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 2
Headquarters: Framingham, MA, United States
Website: xeneticbio.com
Officers: Mr. James F. Parslow CFO, COO, Interim CEO & Corporate Secretary

SEAS

Seasonality · XBIO

2016–2026 · monthly returns

Strongest month Jun +26.88%Weakest month May −13.20%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	2.3	14.0	5.9	13.1	4.0	-7.6	-12.9	65.3	-44.6	-9.5			−3.2%
2025	8.0	-9.0	-33.4	8.8	5.6	30.7	-17.3	-12.0	10.2	6.4	-21.3	-17.5	−45.6%
2024	8.7	10.4	-9.0	14.1	-9.3	4.4	5.4	-4.7	5.6	-5.4	4.3	-6.3	+15.7%
2023	152.6	-27.8	-21.9	3.4	-28.9	9.8	18.6	3.1	22.2	-37.1	6.3	5.3	+21.1%
2022	-20.9	-6.9	7.4	-27.1	6.9	0.8	13.2	-16.2	-29.3	-12.7	-6.2	-35.2	−77.9%
2021	16.2	0.8	-8.8	-10.1	-2.6	6.8	99.5	-26.8	-31.2	-18.5	-15.0	-9.2	−36.8%
2020	-1.4	-30.4	-25.0	24.8	8.5	1.6	14.7	-11.1	-13.0	-4.5	31.9	78.9	+41.7%
2019	13.4	23.7	-15.7	-25.8	-52.8	37.9	-78.6	-31.1	-27.9	1.1	1.7	17.1	−92.7%
2018	8.9	-6.7	10.3	-16.7	-12.8	161.5	-27.7	0.7	-4.7	-13.4	34.7	-50.3	−14.5%
2017	14.7	-15.4	9.1	3.0	-33.4	-11.5	13.8	-22.9	-16.5	5.9	-0.9	-9.5	−55.4%
2016							-12.7	13.5	-10.9	2.2	-19.1	15.6	−15.7%

INSD

Insider Activity · XBIO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Apr 20, 2026	Parslow James FChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	100K	—

13F

Investors Holding XBIO

latest 13F filings of 29 followed managers

Investors holding XBIO
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$341.8K	0.00%	117.44K	−15%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

XBIO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

XBIO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Xenetic Biosciences, Inc.

Seasonality · XBIO

Insider Activity · XBIO

Congress Trades · XBIO

Investors Holding XBIO

Investors Holding XBIO

Congress Trades · XBIO

Insider Activity · XBIO

Seasonality · XBIO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Xenetic Biosciences, Inc.

Earnings & Dividends

News